Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by SlateStone Wealth LLC

SlateStone Wealth LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,672 shares of the medical research company’s stock after buying an additional 524 shares during the period. SlateStone Wealth LLC’s holdings in Thermo Fisher Scientific were worth $3,471,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Greenwich Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 12.1% in the 4th quarter. Greenwich Wealth Management LLC now owns 595 shares of the medical research company’s stock worth $310,000 after buying an additional 64 shares during the last quarter. Avalon Trust Co raised its holdings in shares of Thermo Fisher Scientific by 6.2% in the 4th quarter. Avalon Trust Co now owns 36,784 shares of the medical research company’s stock worth $19,136,000 after purchasing an additional 2,162 shares during the period. one8zero8 LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $3,405,000. Choate Investment Advisors raised its holdings in shares of Thermo Fisher Scientific by 6.0% in the 4th quarter. Choate Investment Advisors now owns 43,211 shares of the medical research company’s stock worth $22,494,000 after purchasing an additional 2,462 shares during the period. Finally, Diversified Enterprises LLC raised its holdings in shares of Thermo Fisher Scientific by 6.6% in the 4th quarter. Diversified Enterprises LLC now owns 1,199 shares of the medical research company’s stock worth $624,000 after purchasing an additional 74 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wells Fargo & Company raised their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Morgan Stanley raised their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Citigroup dropped their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Stock Up 2.9 %

Shares of Thermo Fisher Scientific stock opened at $523.44 on Friday. The business’s fifty day moving average price is $548.54 and its two-hundred day moving average price is $559.17. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market capitalization of $197.47 billion, a P/E ratio of 31.67, a PEG ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.33%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,900 shares of company stock valued at $13,106,062. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.